BC Week In Review | Sep 28, 2018
Financial News

Gene therapy play LogicBio proposes IPO

Gene therapy company LogicBio Therapeutics Inc. (Cambridge, Mass.) proposed to raise up to $86 million in an IPO on NASDAQ underwritten by Jefferies, Barclays, William Blair and Chardan. LogicBio is developing gene therapies to address...
BC Extra | Sep 26, 2018
Financial News

Gene therapy play LogicBio proposes IPO

Gene therapy company LogicBio Therapeutics Inc. (Cambridge, Mass.) proposed to raise up to $86 million in an IPO on NASDAQ underwritten by Jefferies, Barclays, William Blair and Chardan. LogicBio is developing gene therapies to address...
BC Week In Review | Jul 16, 2012
Company News

Le Groupe Pharmaceutique Boivin, Recordati sales and marketing update

Le Groupe Pharmaceutique Boivin , Montreal, Quebec   Recordati S.p.A. (Milan:REC), Milan, Italy   Business: Pharmaceuticals   Recordati's Orphan Europe subsidiary granted Medunik Canada, a part of Le Group Pharmaceutique, exclusive rights in Canada to market...
BC Week In Review | Jun 6, 2011
Clinical News

Carbaglu carglumic acid regulatory update

The European Commission approved an expanded label for Recordati's Carbaglu carglumic acid to include the treatment of hyperammonemia due to isovaleric acidemia, methylmalonic acidemia and propionic acidemia. Carbaglu is approved in the U.S. and Europe...
BC Week In Review | Apr 25, 2011
Clinical News

Carbaglu carglumic acid regulatory update

EMA's CHMP issued a positive opinion to extend the indication for Carbaglu carglumic acid from Recordati to include the treatment of hyperammonemia due to isovaleric acidemia, methylmalonic acidemia and propionic acidemia. Carbaglu is approved in...
BC Week In Review | Mar 22, 2010
Clinical News

Carbaglu regulatory update

FDA approved an NDA from Recordati for Carbaglu carglumic acid to treat hyperammonemia due to hepatic enzyme N-acetylglutamate synthetase (NAGS) deficiency, an inherited disorder that causes ammonia to accumulate in the blood. Carbaglu has Orphan...
BC Extra | Mar 18, 2010
Company News

FDA approves Carbaglu

FDA approved an NDA from Recordati S.p.A. (Milan:REC) for Carbaglu carglumic acid to treat hyperammonemia due to hepatic enzyme N-acetylglutamate synthetase (NAGS) deficiency, an inherited disorder that causes ammonia to accumulate in the blood....
BC Week In Review | Jan 18, 2010
Clinical News

Carbaglu regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 12-0 that the risk-benefit profile of Carbaglu carglumic acid from Recordati supports its approval to treat hyperammonemia due to hepatic enzyme N-acetylglutamate synthetase (NAGS) deficiency, an inherited...
BC Extra | Jan 14, 2010
Top Story

FDA panel backs Carbaglu

FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 12-0 on Wednesday that the risk-benefit profile of Carbaglu carglumic acid from Recordati S.p.A. (Milan:REC) supports its approval to treat hyperammonemia due to hepatic enzyme N-acetylglutamate synthetase...
BC Extra | Jan 12, 2010
Company News

FDA posts Carbaglu briefing documents

FDA posted briefing documents ahead of Wednesday's Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss an NDA from Recordati S.p.A. (Milan:REC) for Carbaglu carglumic acid to treat hyperammonemia due to hepatic enzyme N-acetylglutamate synthetase...
Items per page:
1 - 10 of 15